Please login to the form below

Not currently logged in
Email:
Password:

migraine

This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from

Latest news

More from news
Approximately 26 fully matching, plus 148 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Eli Lilly/Dong Pharmaceuticals’ 5-HT1f agonist Reyvow was approved in the US in October 2019 as the first acute treatment for migraine in 20 years. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    pipeline. He argues, however, that layering in products like Allergan’s blockbuster wrinkle and migraine treatment Botox will improve near-term cashflow and help fund the roll-out of a new ... year. Botox is facing tougher competition in the market

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,

  • Deal Watch January 2018

    Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine.  In exchange for the licence, Alder will withdraw its appeal

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics